On November 26, 2018 SmartTarget Ltd, a spinout of UCL (University College London) that has developed a CE-approved device for precision prostate biopsy and focal therapy, is reported the appointment of Bruce Lynn as its CEO (Press release, UCLB, NOV 26, 2018, View Source [SID1234531605]). Mark Kirby who has held the role of interim CEO, steps up to the role of Chairman of the board.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Lynn is a 30 year veteran of the software industry having built a range of businesses including Kenan Systems UK, Microsoft UK digital technology, and Red Bee Piero. Most recently he has been working in the medical imaging sector with a number of organisations including Brandon Medical, Enteric HTC, Motilent, and Forclarity. Lynn commented "Real-time enhancement of imaging in surgery is poised at a major inflection point. Whereas ‘sci-fi’ technologies such as tele-robotics and augmented reality will no doubt play a part in the operating room of the future, the theatre is already seeing massive benefits in patient outcomes and cost of delivery by applying innovative modelling software to traditional clinical interventions. SmartTarget has successfully cracked one of the most demanding and requested technical challenges which is the mapping of high quality diagnostic imaging such as mp-MRI onto a lower quality imaging modality that is available to the clinician during the intervention, such as ultrasound, whilst accommodating dynamically and accurately for movement and deformation in the target organ even during the procedure." SmartTarget Director and UCLB Senior Business Manager Marina Santilli commented, "We are delighted to welcome Bruce to the SmartTarget team as we look to the company to capitalise on its best in class fusion software for prostate imaging for better informed biopsy and treatment targeting. The company’s strong academic pedigree and ongoing links with UCL’s medical imaging researchers is an asset that we hope to exploit further as Bruce brings his significant industry experience to develop a roadmap and vision that aims to bring all clinicians the benefit of advanced imaging into their operating room."